Skip to main content
SpringerLink
Log in

Therapeutic Potential of HDPs as Immunomodulatory Agents

  • Protocol
  • First Online:
Antimicrobial Peptides

Part of the book series: Methods in Molecular Biology ((MIMB,volume 618))

Abstract

One of the most significant advances in medical history is the discovery and development of antibiotics, which in the middle of last century was flourishing and appeared to be the ultimate solution to the treatment of life-threatening human bacterial diseases. However, lately there has been a huge decline in the rate of discovery of new antimicrobial intervention strategies in parallel with an increasing incidence of multidrug-resistant pathogens; if these circumstances do not change we will continue to approach the end of the antibiotic era. Facing this dark future, scientists are considering new strategies for intervention tailored around the appropriate (selective) stimulation of the host’s immune system, and particularly rapid acting innate immunity, as an alternative to direct targeting of microbial pathogens. One recent player in such an immunomodulatory strategy is the naturally occurring host defence peptides (HDP) and their synthetic innate defence regulator (IDR) analogues. In this chapter, we will discuss the potential therapeutic use of HDPs and IDRs as immunomodulatory agents.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Hamill, P., Brown, K., Jenssen, H., and Hancock, R. E. W. (2008) Novel anti-infectives: is host defence the answer?. Curr. Opin. Biotechnol. 19, 628–636.

    Article  PubMed  CAS  Google Scholar 

  2. Lai, Y. and Gallo, R. L. (2008) Toll-like receptors in skin infections and inflammatory diseases. Infect. Disord. Drug Targets 8, 144–155.

    Article  PubMed  CAS  Google Scholar 

  3. O’Neill, L. A. (2006) Targeting signal transduction as a strategy to treat inflammatory diseases. Nat. Rev. Drug Discov. 5, 549–563.

    Article  PubMed  CAS  Google Scholar 

  4. Kanzler, H., Barrat, F. J., Hessel, E. M., and Coffman, R. L. (2007) Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat. Med. 13, 552–559.

    Article  PubMed  CAS  Google Scholar 

  5. Romagne, F. (2007) Current and future drugs targeting one class of innate immunity receptors: the Toll-like receptors. Drug Discov. Today 12, 80–87.

    Article  PubMed  CAS  Google Scholar 

  6. Wales, J., Andreakos, E., Feldmann, M., and Foxwell, B. (2007) Targeting intracellular mediators of pattern-recognition receptor signalling to adjuvant vaccination. Biochem. Soc. Trans. 35, 1501–1503.

    Article  PubMed  CAS  Google Scholar 

  7. Creagh, E. M. and O’Neill, L. A. (2006) TLRs, NLRs and RLRs: a trinity of pathogen sensors that co-operate in innate immunity. Trends Immunol. 27, 352–357.

    Article  PubMed  CAS  Google Scholar 

  8. Alper, S., Laws, R., Lackford, B., Boyd, W. A., Dunlap, P., Freedman, J. H., and Schwartz, D. A. (2008) Identification of innate immunity genes and pathways using a comparative genomics approach. Proc. Natl. Acad. Sci. USA 105, 7016–7021.

    Article  PubMed  CAS  Google Scholar 

  9. Tegner, J., Nilsson, R., Bajic, V. B., Bjorkegren, J., and Ravasi, T. (2006) Systems biology of innate immunity. Cell. Immunol. 244, 105–109.

    Article  PubMed  CAS  Google Scholar 

  10. Lynn, D. J., Winsor, G. L., Chan, C., Richard, N., Laird, M. R., Barsky, A., Gardy, J. L., Roche, F. M., Chan, T. H., Shah, N., Lo, R., Naseer, M., Que, J., Yau, M., Acab, M., Tulpan, D., Whiteside, M. D., Chikatamarla, A., Mah, B., Munzner, T., Hokamp, K., Hancock, R. E. W., and Brinkman, F. S. (2008) InnateDB: facilitating systems-level analyses of the mammalian innate immune response. Mol. Syst. Biol. 4, 218.

    Article  PubMed  CAS  Google Scholar 

  11. Korb, M., Rust, A. G., Thorsson, V., Battail, C., Li, B., Hwang, D., Kennedy, K. A., Roach, J. C., Rosenberger, C. M., Gilchrist, M., Zak, D., Johnson, C., Marzolf, B., Aderem, A., Shmulevich, I., and Bolouri, H. (2008) The innate immune database (IIDB). BMC Immunol. 9, 7.

    Google Scholar 

  12. Hancock, R. E. W. and Sahl, H. G. (2006) Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat. Biotechnol. 24, 1551–1157.

    Google Scholar 

  13. Oppenheim, J. J. and Yang, D. (2005) Alarmins: chemotactic activators of immune responses. Curr. Opin. Immunol. 17, 359–365.

    Article  PubMed  CAS  Google Scholar 

  14. Zasloff, M. (2002) Antimicrobial peptides of multicellular organisms. Nature 415, 389–395.

    Article  PubMed  CAS  Google Scholar 

  15. Fjell, C. D., Hancock, R. E. W., and Cherkasov, A. (2007) AMPer: a database and an automated discovery tool for antimicrobial peptides. Bioinformatics 23, 1148–1155.

    Article  PubMed  CAS  Google Scholar 

  16. Jenssen, H., Hamill, P., and Hancock, R. E. W. (2006) Peptide antimicrobial agents. Clin. Microbiol. Rev. 19, 491–511.

    Article  PubMed  CAS  Google Scholar 

  17. Hancock, R. E. W. (2001) Cationic peptides: effectors in innate immunity and novel antimicrobials. Lancet Infect. Dis. 1, 156–164.

    Article  PubMed  CAS  Google Scholar 

  18. Brogden, K. A. (2005) Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria?. Nat. Rev. Microbiol. 3, 238–250.

    Article  PubMed  CAS  Google Scholar 

  19. Wu, M., Maier, E., Benz, R., and Hancock, R. E. W. (1999) Mechanism of interaction of different classes of cationic antimicrobial peptides with planar bilayers and with the cytoplasmic membrane of Escherichia coli. Biochemistry 38, 7235–7242.

    Article  PubMed  CAS  Google Scholar 

  20. Hallock, K. J., Lee, D. K., and Ramamoorthy, A. (2003) MSI-78, an analogue of the magainin antimicrobial peptides, disrupts lipid bilayer structure via positive curvature strain. Biophys. J. 84, 3052–3060.

    Article  PubMed  CAS  Google Scholar 

  21. Henzler Wildman, K. A., Lee, D. K., and Ramamoorthy, A. (2003) Mechanism of lipid bilayer disruption by the human antimicrobial peptide, LL-37. Biochemistry 42, 6545–6558.

    Article  PubMed  CAS  Google Scholar 

  22. Matsuzaki, K., Murase, O., Fujii, N., and Miyajima, K. (1996) An antimicrobial peptide, magainin 2, induced rapid flip-flop of phospholipids coupled with pore formation and peptide translocation. Biochemistry 35, 11361–11368.

    Article  PubMed  CAS  Google Scholar 

  23. Yang, L., Harroun, T. A., Weiss, T. M., Ding, L., and Huang, H. W. (2001) Barrel-Stave model or Toroidal model? A case study on melittin pores. Biophys. J. 81, 1475–1485.

    Article  PubMed  Google Scholar 

  24. Ehrenstein, G. and Lecar, H. (1977) Electrically gated ionic channels in lipid bilayers. Q. Rev. Biophys. 10, 1–34.

    Article  PubMed  CAS  Google Scholar 

  25. Pouny, Y., Rapaport, D., Mor, A., Nicolas, P., and Shai, Y. (1992) Interaction of antimicrobial dermaseptin and its fluorescently labeled analogues with phospholipid membranes. Biochemistry 31, 12416–12423.

    Article  PubMed  CAS  Google Scholar 

  26. Zhang, L., Rozek, A., and Hancock, R. E. W. (2001) Interaction of cationic antimicrobial peptides with model membranes. J. Biol. Chem. 276, 35714–35722.

    Article  PubMed  CAS  Google Scholar 

  27. Park, C. B., Kim, H. S., and Kim, S. C. (1998) Mechanism of action of the antimicrobial peptide buforin II: buforin II kills microorganisms by penetrating the cell membrane and inhibiting cellular functions. Biochem. Biophys. Res. Commun. 244, 253–257.

    Article  PubMed  CAS  Google Scholar 

  28. Patrzykat, A., Friedrich, C. L., Zhang, L., Mendoza, V., and Hancock, R. E. W. (2002) Sublethal concentrations of pleurocidin-derived antimicrobial peptides inhibit macromolecular synthesis in escherichia coli. Antimicrob. Agents Chemother. 46, 605–614.

    Article  PubMed  CAS  Google Scholar 

  29. Subbalakshmi, C. and Sitaram, N. (1998) Mechanism of antimicrobial action of indolicidin. FEMS Microbiol. Lett. 160, 91–96.

    Article  PubMed  CAS  Google Scholar 

  30. Lehrer, R. I., Barton, A., Daher, K. A., Harwig, S. S., Ganz, T., and Selsted, M. E. (1989) Interaction of human defensins with Escherichia coli. Mechanism of bactericidal activity. J. Clin. Invest. 84, 553–561.

    Article  PubMed  CAS  Google Scholar 

  31. Boman, H. G., Agerberth, B., and Boman, A. (1993) Mechanisms of action on Escherichia coli of cecropin P1 and PR-39, two antibacterial peptides from pig intestine. Infect. Immun. 61, 2978–2984.

    PubMed  CAS  Google Scholar 

  32. Friedrich, C. L., Rozek, A., Patrzykat, A., and Hancock, R. E. W. (2001) Structure and mechanism of action of an indolicidin peptide derivative with improved activity against gram-positive bacteria. J. Biol. Chem. 276, 24015–24022.

    Article  PubMed  CAS  Google Scholar 

  33. Kragol, G., Lovas, S., Varadi, G., Condie, B. A., Hoffmann, R., and Otvos, L., Jr. (2001) The antibacterial peptide pyrrhocoricin inhibits the ATPase actions of DnaK and prevents chaperone-assisted protein folding. Biochemistry 40, 3016–3026.

    Article  PubMed  CAS  Google Scholar 

  34. Otvos, L., Jr., O, I., Rogers, M. E., Consolvo, P. J., Condie, B. A., Lovas, S., Bulet, P., and Blaszczyk-Thurin, M. (2000) Interaction between heat shock proteins and antimicrobial peptides. Biochemistry 39, 14150–14159.

    Article  PubMed  CAS  Google Scholar 

  35. Hechard, Y. and Sahl, H. G. (2002) Mode of action of modified and unmodified bacteriocins from Gram-positive bacteria. Biochimie 84, 545–557.

    Article  PubMed  CAS  Google Scholar 

  36. Podolsky, D. K. (2002) Inflammatory bowel disease. N. Engl. J. Med. 347, 417–429.

    Article  PubMed  CAS  Google Scholar 

  37. Wehkamp, J., Fellermann, K., Herrlinger, K. R., Baxmann, S., Schmidt, K., Schwind, B., Duchrow, M., Wohlschlager, C., Feller, A. C., and Stange, E. F. (2002) Human beta-defensin 2 but not beta-defensin 1 is expressed preferentially in colonic mucosa of inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 14, 745–752.

    Article  PubMed  CAS  Google Scholar 

  38. Wehkamp, J., Harder, J., Weichenthal, M., Mueller, O., Herrlinger, K. R., Fellermann, K., Schroeder, J. M., and Stange, E. F. (2003) Inducible and constitutive beta-defensins are differentially expressed in Crohn’s disease and ulcerative colitis. Inflamm. Bowel. Dis. 9, 215–223.

    Article  PubMed  Google Scholar 

  39. Schauber, J., Rieger, D., Weiler, F., Wehkamp, J., Eck, M., Fellermann, K., Scheppach, W., Gallo, R. L., and Stange, E. F. (2006) Heterogeneous expression of human cathelicidin hCAP18/LL-37 in inflammatory bowel diseases. Eur. J. Gastroenterol. Hepatol. 18, 615–621.

    Article  PubMed  CAS  Google Scholar 

  40. Wehkamp, J., Schmid, M., and Stange, E. F. (2007) Defensins and other antimicrobial peptides in inflammatory bowel disease. Curr. Opin. Gastroenterol. 23, 370–378.

    Article  PubMed  CAS  Google Scholar 

  41. Gudmundsson, G. H., Agerberth, B., Odeberg, J., Bergman, T., Olsson, B., and Salcedo, R. (1996) The human gene FALL39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes. Eur. J. Biochem. 238, 325–332.

    Article  PubMed  CAS  Google Scholar 

  42. Gallo, R. L., Kim, K. J., Bernfield, M., Kozak, C. A., Zanetti, M., Merluzzi, L., and Gennaro, R. (1997) Identification of CRAMP, a cathelin-related antimicrobial peptide expressed in the embryonic and adult mouse. J. Biol. Chem. 272, 13088–13093.

    Article  PubMed  CAS  Google Scholar 

  43. Nizet, V., Ohtake, T., Lauth, X., Trowbridge, J., Rudisill, J., Dorschner, R. A., Pestonjamasp, V., Piraino, J., Huttner, K., and Gallo, R. L. (2001) Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature 414, 454–457.

    Article  PubMed  CAS  Google Scholar 

  44. Putsep, K., Carlsson, G., Boman, H. G., and Andersson, M. (2002) Deficiency of antibacterial peptides in patients with morbus Kostmann: an observation study. Lancet 360, 1144–1149.

    Article  PubMed  CAS  Google Scholar 

  45. Cherkasov, A., Hilpert, K., Jenssen, H., Fjell, C. D., Waldbrook, M., Mullaly, S. C., Volkmer, R., and Hancock, R. E. W. (2008) Use of artificial intelligence in the design of small peptide antibiotics effective against a broad spectrum of highly antibiotic-resistant superbugs. ACS Chem. Biol. 1, 65–74.

    Google Scholar 

  46. Bowdish, D. M., Davidson, D. J., Lau, Y. E., Lee, K., Scott, M. G., and Hancock, R. E. W. (2005) Impact of LL-37 on anti-infective immunity. J. Leukoc. Biol. 77, 451–459.

    Article  PubMed  CAS  Google Scholar 

  47. Scott, M. G., Davidson, D. J., Gold, M. R., Bowdish, D., and Hancock, R. E. W. (2002) The human antimicrobial peptide LL-37 is a multifunctional modulator of innate immune responses. J. Immunol. 169, 3883–3891.

    PubMed  CAS  Google Scholar 

  48. Fukumoto, K., Nagaoka, I., Yamataka, A., Kobayashi, H., Yanai, T., Kato, Y., and Miyano, T. (2005) Effect of antibacterial cathelicidin peptide CAP18/LL-37 on sepsis in neonatal rats. Pediatr. Surg. Int. 21, 20–24.

    Article  PubMed  Google Scholar 

  49. McGwire, B. S., Olson, C. L., Tack, B. F., and Engman, D. M. (2003) Killing of African trypanosomes by antimicrobial peptides. J. Infect. Dis. 188, 146–152.

    Article  PubMed  Google Scholar 

  50. Joly, S., Maze, C., McCray, P. B., Jr., and Guthmiller, J. M. (2004) Human beta-defensins 2 and 3 demonstrate strain-selective activity against oral microorganisms. J. Clin. Microbiol. 42, 1024–1029.

    Article  PubMed  CAS  Google Scholar 

  51. Giacometti, A., Cirioni, O., Ghiselli, R., Mocchegiani, F., D’Amato, G., Circo, R., Orlando, F., Skerlavaj, B., Silvestri, C., Saba, V., Zanetti, M., and Scalise, G. (2004) Cathelicidin peptide sheep myeloid antimicrobial peptide-29 prevents endotoxin-induced mortality in rat models of septic shock. Am. J. Respir. Crit. Care Med. 169, 187–194.

    Article  PubMed  Google Scholar 

  52. Brogden, K. A., Nordholm, G., and Ackermann, M. (2007) Antimicrobial activity of cathelicidins BMAP28, SMAP28, SMAP29, and PMAP23 against Pasteurella multocida is more broad-spectrum than host species specific. Vet. Microbiol. 119, 76–81.

    Article  PubMed  CAS  Google Scholar 

  53. Andersson, L., Blomberg, L., Flegel, M., Lepsa, L., Nilsson, B., and Verlander, M. (2000) Large-scale synthesis of peptides. Biopolymers 55, 227–250.

    Article  PubMed  CAS  Google Scholar 

  54. Schneider, S. E., Bray, B. L., Mader, C. J., Friedrich, P. E., Anderson, M. W., Taylor, T. S., Boshernitzan, N., Niemi, T. E., Fulcher, B. C., Whight, S. R., White, J. M., Greene, R. J., Stoltenberg, L. E., and Lichty, M. (2005) Development of HIV fusion inhibitors. J. Pept. Sci. 11, 744–753.

    Article  PubMed  CAS  Google Scholar 

  55. Mygind, P. H., Fischer, R. L., Schnorr, K. M., Hansen, M. T., Sonksen, C. P., Ludvigsen, S., Raventos, D., Buskov, S., Christensen, B., De Maria, L., Taboureau, O., Yaver, D., Elvig-Jorgensen, S. G., Sorensen, M. V., Christensen, B. E., Kjaerulff, S., Frimodt-Moller, N., Lehrer, R. I., Zasloff, M., and Kristensen, H. H. (2005) Plectasin is a peptide antibiotic with therapeutic potential from a saprophytic fungus. Nature 437, 975–980.

    Article  PubMed  CAS  Google Scholar 

  56. Gottlieb, C. T., Thomsen, L. E., Ingmer, H., Mygind, P. H., Kristensen, H. H., and Gram, L. (2008) Antimicrobial peptides effectively kill a broad spectrum of Listeria monocytogenes and Staphylococcus aureus strains independently of origin, sub-type, or virulence factor expression. BMC Microbiol. 8, 205.

    Article  PubMed  CAS  Google Scholar 

  57. Hara, S., Mukae, H., Sakamoto, N., Ishimoto, H., Amenomori, M., Fujita, H., Ishimatsu, Y., Yanagihara, K., and Kohno, S. (2008) Plectasin has antibacterial activity and no affect on cell viability or IL-8 production. Biochem. Biophys. Res. Commun. 374, 709–713.

    Article  PubMed  CAS  Google Scholar 

  58. Chatterjee, J., Gilon, C., Hoffman, A., and Kessler, H. (2008) N-methylation of peptides: a new perspective in medicinal chemistry. Acc. Chem. Res. 41, 1331–1342.

    Article  PubMed  CAS  Google Scholar 

  59. Biron, E., Chatterjee, J., Ovadia, O., Langenegger, D., Brueggen, J., Hoyer, D., Schmid, H. A., Jelinek, R., Gilon, C., Hoffman, A., and Kessler, H. (2008) Improving oral bioavailability of peptides by multiple N-methylation: somatostatin analogues. Angew Chem. Int. Ed. Engl. 47, 2595–2599.

    Article  PubMed  CAS  Google Scholar 

  60. Kobsa, S. and Saltzman, W. M. (2008) Bioengineering approaches to controlled protein delivery. Pediatr. Res. 63, 513–519.

    Article  PubMed  Google Scholar 

  61. Barnard, D. L. (2001) Pegasys (Hoffmann-La Roche). Curr. Opin. Investig. Drugs 2, 1530–1538.

    PubMed  CAS  Google Scholar 

  62. Giannis, A. and Kolter, T. (1993) Pepidomimetics for receptor ligands – discovery, development, and medical perspectives. Angew. Chem. Int. Ed. 32, 24.

    Article  Google Scholar 

  63. Wiley, R. A. and Rich, D. H. (1993) Peptidomimetics derived from natural products. Med. Res. Rev. 13, 327–384.

    Article  PubMed  CAS  Google Scholar 

  64. Sanborn, T. J., Wu, C. W., Zuckermann, R. N., and Barron, A. E. (2002) Extreme stability of helices formed by water-soluble poly-N-substituted glycines (polypeptoids) with alpha-chiral side chains. Biopolymers 63, 12–20.

    Article  PubMed  CAS  Google Scholar 

  65. Domagk, G. (1935) A report on the chemotherapy of bacterial infections. Deut. Med. Woch. Ixi:250.

    Google Scholar 

  66. Trefouel, J., Nitti, F., and Bovet, D. (1935) Activity of p-aminophenylsulfamide in the experimental streptococcal infections of the mouse and rabbit. CR Seances Soc. Biol. 120, 756.

    CAS  Google Scholar 

  67. Lamb, H. M. and Wiseman, L. R. (1998) Pexiganan acetate. Drugs 56, 1047–1052, discussion 1053–1054.

    Article  PubMed  CAS  Google Scholar 

  68. Trotti, A., Garden, A., Warde, P., Symonds, P., Langer, C., Redman, R., Pajak, T. F., Fleming, T. R., Henke, M., Bourhis, J., Rosenthal, D. I., Junor, E., Cmelak, A., Sheehan, F., Pulliam, J., Devitt-Risse, P., Fuchs, H., Chambers, M., O’Sullivan, B., and Ang, K. K. (2004) A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy. Int. J. Radiat. Oncol. Biol. Phys. 58, 674–681.

    Article  PubMed  CAS  Google Scholar 

  69. van Saene, H., van Saene, J., Silvestri, L., de la Cal, M., Sarginson, R., and Zandstra, D. (2007) Iseganan failure due to the wrong pharmaceutical technology. Chest 132, 1412.

    Article  PubMed  Google Scholar 

  70. Kollef, M., Pittet, D., Sanchez Garcia, M., Chastre, J., Fagon, J. Y., Bonten, M., Hyzy, R., Fleming, T. R., Fuchs, H., Bellm, L., Mercat, A., Manez, R., Martinez, A., Eggimann, P., Daguerre, M., and Luyt, C. E. (2006) A randomized double-blind trial of iseganan in prevention of ventilator-associated pneumonia. Am. J. Respir. Crit. Care Med. 173, 91–97.

    Article  PubMed  CAS  Google Scholar 

  71. Fritsche, T. R., Rhomberg, P. R., Sader, H. S., and Jones, R. N. (2008) Antimicrobial activity of omiganan pentahydrochloride tested against contemporary bacterial pathogens commonly responsible for catheter-associated infections. J. Antimicrob. Chemother. 61, 1092–1098.

    Article  PubMed  CAS  Google Scholar 

  72. Fritsche, T. R., Rhomberg, P. R., Sader, H. S., and Jones, R. N. (2008) Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections. Antimicrob. Agents Chemother. 52, 1187–1189.

    Article  PubMed  CAS  Google Scholar 

  73. Scott, M. G., Dullaghan, E., Mookherjee, N., Glavas, N., Waldbrook, M., Thompson, A., Wang, A., Lee, K., Doria, S., Hamill, P., Yu, J. J., Li, Y., Donini, O., Guarna, M. M., Finlay, B. B., North, J. R., and Hancock, R. E. W. (2007) An anti-infective peptide that selectively modulates the innate immune response. Nat. Biotechnol. 25, 465–472.

    Article  PubMed  CAS  Google Scholar 

  74. Lai, X. Z., Feng, Y., Pollard, J., Chin, J. N., Rybak, M. J., Bucki, R., Epand, R. F., Epand, R. M., and Savage, P. B. (2008) Ceragenins: cholic acid-based mimics of antimicrobial peptides. Acc. Chem. Res. 41, 1233–1240.

    Article  PubMed  CAS  Google Scholar 

  75. Chin, J. N., Rybak, M. J., Cheung, C. M., and Savage, P. B. (2007) Antimicrobial activities of ceragenins against clinical isolates of resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 51, 1268–1273.

    Article  PubMed  CAS  Google Scholar 

  76. Van Bambeke, F., Mingeot-Leclercq, M. P., Struelens, M. J., and Tulkens, P. M. (2008) The bacterial envelope as a target for novel anti-MRSA antibiotics. Trends Pharmacol. Sci. 29, 124–134.

    Article  PubMed  CAS  Google Scholar 

  77. Savage, P. B., Li, C., Taotafa, U., Ding, B., and Guan, Q. (2002) Antibacterial properties of cationic steroid antibiotics. FEMS Microbiol. Lett. 217, 1–7.

    Article  PubMed  CAS  Google Scholar 

  78. Savage, P. B., Pollard, J., Feng, Y., Reddy, L. K., and Genberg, C. (2008): Use of a Ceragenin-Based Coating to Prevent Bacterial Colonization of Urinary Catheters. In Interscience Conference on Antimicrobial Agents & Chemotherapy pp. Poster K–1479.

    Google Scholar 

  79. Beckloff, N., Laube, D., Castro, T., Furgang, D., Park, S., Perlin, D., Clements, D., Tang, H., Scott, R. W., Tew, G. N., and Diamond, G. (2007) Activity of an antimicrobial peptide mimetic against planktonic and biofilm cultures of oral pathogens. Antimicrob. Agents Chemother. 51, 4125–4132.

    Article  PubMed  CAS  Google Scholar 

  80. Scott, R. W., DeGrado, W. F., and Tew, G. N. (2008) De novo designed synthetic mimics of antimicrobial peptides. Curr. Opin. Biotechnol. 19, 620–627.

    Article  PubMed  CAS  Google Scholar 

  81. Viola, A. and Luster, A. D. (2008) Chemokines and their receptors: drug targets in immunity and inflammation. Annu. Rev. Pharmacol. Toxicol 48, 171–197.

    Article  PubMed  CAS  Google Scholar 

  82. Sawai, M. V., Jia, H. P., Liu, L., Aseyev, V., Wiencek, J. M., McCray, P. B., Jr., Ganz, T., Kearney, W. R., and Tack, B. F. (2001) The NMR structure of human beta-defensin-2 reveals a novel alpha-helical segment. Biochemistry 40, 3810–3816.

    Article  PubMed  CAS  Google Scholar 

  83. Mandard, N., Sodano, P., Labbe, H., Bonmatin, J. M., Bulet, P., Hetru, C., Ptak, M., and Vovelle, F. (1998) Solution structure of thanatin, a potent bactericidal and fungicidal insect peptide, determined from proton two-dimensional nuclear magnetic resonance data. Eur. J. Biochem. 256, 404–410.

    Article  PubMed  CAS  Google Scholar 

  84. Wang, G. (2008) Structures of human host defense cathelicidin LL-37 and its smallest antimicrobial peptide kr-12 in lipid micelles. J. Biol. Chem. 283, 32637–32643.

    Article  PubMed  CAS  Google Scholar 

  85. Rozek, A., Friedrich, C. L., and Hancock, R. E. W. (2000) Structure of the bovine antimicrobial peptide indolicidin bound to dodecylphosphocholine and sodium dodecyl sulfate micelles. Biochemistry 39, 15765–15774.

    Article  PubMed  CAS  Google Scholar 

  86. Koradi, R., Billeter, M., and Wuthrich, K. (1996) MOLMOL: a program for display and analysis of macromolecular structures. J. Mol. Graph. 14, 51–55, 29–32.

    Google Scholar 

  87. Bowdish, D. M., Davidson, D. J., Scott, M. G., and Hancock, R. E. W. (2005) Immunomodulatory activities of small host defense peptides. Antimicrob. Agents Chemother. 49, 1727–, 1732.

    Article  PubMed  CAS  Google Scholar 

  88. Mookherjee, N., Brown, K. L., Bowdish, D. M., Doria, S., Falsafi, R., Hokamp, K., Roche, F. M., Mu, R., Doho, G. H., Pistolic, J., Powers, J. P., Bryan, J., Brinkman, F. S., and Hancock, R. E. W. (2006) Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37. J. Immunol. 176, 2455–2464.

    PubMed  CAS  Google Scholar 

  89. Mookherjee, N., Wilson, H. L., Doria, S., Popowych, Y., Falsafi, R., Yu, J. J., Li, Y., Veatch, S., Roche, F. M., Brown, K. L., Brinkman, F. S., Hokamp, K., Potter, A., Babiuk, L. A., Griebel, P. J., and Hancock, R. E. W. (2006) Bovine and human cathelicidin cationic host defense peptides similarly suppress transcriptional responses to bacterial lipopolysaccharide. J. Leukoc. Biol. 80, 1563–1574.

    Article  PubMed  CAS  Google Scholar 

  90. Bowdish, D. M. and Hancock, R. E. W. (2005) Anti-endotoxin properties of cationic host defence peptides and proteins. J. Endotoxin Res. 11, 230–236.

    PubMed  Google Scholar 

  91. Ohgami, K., Ilieva, I. B., Shiratori, K., Isogai, E., Yoshida, K., Kotake, S., Nishida, T., Mizuki, N., and Ohno, S. (2003) Effect of human cationic antimicrobial protein 18 Peptide on endotoxin-induced uveitis in rats. Invest Ophthalmol. Vis. Sci. 44, 4412–4418.

    Article  PubMed  Google Scholar 

  92. Davidson, D. J., Currie, A. J., Reid, G. S., Bowdish, D. M., MacDonald, K. L., Ma, R. C., Hancock, R. E. W., and Speert, D. P. (2004) The cationic antimicrobial peptide LL-37 modulates dendritic cell differentiation and dendritic cell-induced T cell polarization. J. Immunol. 172, 1146–1156.

    PubMed  CAS  Google Scholar 

  93. Tjabringa, G. S., Ninaber, D. K., Drijfhout, J. W., Rabe, K. F., and Hiemstra, P. S. (2006) Human cathelicidin LL-37 is a chemoattractant for eosinophils and neutrophils that acts via formyl-peptide receptors. Int. Arch. Allergy Immunol. 140, 103–112.

    Article  PubMed  CAS  Google Scholar 

  94. Chertov, O., Michiel, D. F., Xu, L., Wang, J. M., Tani, K., Murphy, W. J., Longo, D. L., Taub, D. D., and Oppenheim, J. J. (1996) Identification of defensin-1, defensin-2, and CAP37/azurocidin as T-cell chemoattractant proteins released from interleukin-8-stimulated neutrophils. J. Biol. Chem. 271, 2935–2940.

    Article  PubMed  CAS  Google Scholar 

  95. Kurosaka, K., Chen, Q., Yarovinsky, F., Oppenheim, J. J., and Yang, D. (2005) Mouse cathelin-related antimicrobial peptide chemoattracts leukocytes using formyl peptide receptor-like 1/mouse formyl peptide receptor-like 2 as the receptor and acts as an immune adjuvant. J. Immunol. 174, 6257–6265.

    PubMed  CAS  Google Scholar 

  96. Territo, M. C., Ganz, T., Selsted, M. E., and Lehrer, R. (1989) Monocyte-chemotactic activity of defensins from human neutrophils. J. Clin. Invest. 84, 2017–2020.

    Article  PubMed  CAS  Google Scholar 

  97. Djanani, A., Mosheimer, B., Kaneider, N. C., Ross, C. R., Ricevuti, G., Patsch, J. R., and Wiedermann, C. J. (2006) Heparan sulfate proteoglycan-dependent neutrophil chemotaxis toward PR-39 cathelicidin. J. Inflam. (Lond) 3, 14.

    Article  CAS  Google Scholar 

  98. Yu, J., Mookherjee, N., Wee, K., Bowdish, D. M., Pistolic, J., Li, Y., Rehaume, L., and Hancock, R. E. W. (2007) Host defense peptide LL-37, in synergy with inflammatory mediator IL-1beta, augments immune responses by multiple pathways. J. Immunol. 179, 7684–7691.

    PubMed  CAS  Google Scholar 

  99. Bowdish, D. M., Davidson, D. J., Speert, D. P., and Hancock, R. E. W. (2004) The human cationic peptide LL-37 induces activation of the extracellular signal-regulated kinase and p38 kinase pathways in primary human monocytes. J. Immunol. 172, 3758–3765.

    PubMed  CAS  Google Scholar 

  100. Lau, Y. E., Rozek, A., Scott, M. G., Goosney, D. L., Davidson, D. J., and Hancock, R. E. W. (2005) Interaction and cellular localization of the human host defense peptide LL-37 with lung epithelial cells. Infect. Immun. 73, 583–591.

    Article  PubMed  CAS  Google Scholar 

  101. Niyonsaba, F., Someya, A., Hirata, M., Ogawa, H., and Nagaoka, I. (2001) Evaluation of the effects of peptide antibiotics human beta-defensins-1/-2 and LL-37 on histamine release and prostaglandin D(2) production from mast cells. Eur J. Immunol. 31, 1066–1075.

    Article  PubMed  CAS  Google Scholar 

  102. Li, J., Post, M., Volk, R., Gao, Y., Li, M., Metais, C., Sato, K., Tsai, J., Aird, W., Rosenberg, R. D., Hampton, T. G., Sellke, F., Carmeliet, P., and Simons, M. (2000) PR39, a peptide regulator of angiogenesis. Nat. Med. 6, 49–55.

    Article  PubMed  CAS  Google Scholar 

  103. Gallo, R. L., Ono, M., Povsic, T., Page, C., Eriksson, E., Klagsbrun, M., and Bernfield, M. (1994) Syndecans, cell surface heparan sulfate proteoglycans, are induced by a proline-rich antimicrobial peptide from wounds. Proc. Natl. Acad. Sci. USA 91, 11035–11039.

    Article  PubMed  CAS  Google Scholar 

  104. Schroeder, J. M. and Harder, J. (2006) Antimicrobial peptides in skin disease. Drug Discov. Today 3, 8.

    Google Scholar 

  105. Melo, M. N., Dugourd, D., and Castanho, M. A. (2006) Omiganan pentahydrochloride in the front line of clinical applications of antimicrobial peptides. Recent Patents Anti-Infect Drug Disc. 1, 201–207.

    Article  CAS  Google Scholar 

  106. Ilyina, E., Roongta, V., and Mayo, K. H. (1997) NMR structure of a de novo designed, peptide 33mer with two distinct, compact beta-sheet folds. Biochemistry 36, 5245–5250.

    Article  PubMed  CAS  Google Scholar 

  107. Mayo, K. H., Haseman, J., Young, H. C., and Mayo, J. W. (2000) Structure-function relationships in novel peptide dodecamers with broad-spectrum bactericidal and endotoxin-neutralizing activities. Biochem. J. 349 Pt 3, 717–728.

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This manuscript is dedicated to the memory of Aaron W.J. Wyatt who tragically passed away on 24 December 2008. Aaron was not only a superb colleague but also a good friend.

The author’s research in this area was supported by the Foundation for the National Institutes of Health, Gates Foundation and Canadian Institutes for Health Research through two separate Grand Challenges in Global Health Initiatives and by Genome British Columbia for the Pathogenomics of Innate Immunity Research Program. REWH is the recipient of a Canada Research Chair.

Author information

Authors and Affiliations

  1. Department of Science, Systems, and Models, Roskilde University, Roskilde, Denmark

    Håvard Jenssen

  2. Centre for Microbial Diseases and Immunity Research, University of British Columbia, Vancouver, BC, Canada

    Robert E. W. Hancock

Authors
  1. Håvard Jenssen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert E. W. Hancock
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. SpiderBiotech S.r.l., Via Ribes 5, Colleretto Giacosa, 10010, Torino, Italy

    Andrea Giuliani

  2. Dipto. Scienze e Tecnologie Biomediche, Università di Cagliari, Monserrato, 09042, Italy

    Andrea C. Rinaldi

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this protocol

Cite this protocol

Jenssen, H., Hancock, R.E.W. (2010). Therapeutic Potential of HDPs as Immunomodulatory Agents. In: Giuliani, A., Rinaldi, A. (eds) Antimicrobial Peptides. Methods in Molecular Biology, vol 618. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60761-594-1_20

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-594-1_20

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-60761-593-4

  • Online ISBN: 978-1-60761-594-1

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation